Barclays Maintains Overweight on Coca-Cola, Raises Price Target to $98
Barclays analyst Lauren Lieberman maintains Coca-Cola (NYSE:KO) with a Overweight and raises the price target from $93 to $98.
Stocks · News reference
Ending a 40-year deal, KFC replaces Pepsi with Coca-Cola at 3,600 U.S. locations as part of its "Kentucky Fried Comeback."
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Barclays analyst Lauren Lieberman maintains Coca-Cola (NYSE:KO) with a Overweight and raises the price target from $93 to $98.
The OAAA announced the 84th Annual OBIE Awards winners, recognizing excellence in out-of-home advertising. Paramount was inducted into the 2026 OBIE Hall of Fame for its creative excellence and commitment to OOH advertising. Random House Publishing Group and Known won the Platinum OBIE Award for 'Steph Curry Shoots the Moon,' while other major brands including Netflix, OpenAI, United Airlines, and Coca-Cola received recognition across various categories.
The Coca-Cola Company is trending Friday after KFC said Thursday that its U.S. restaurants will replace PepsiCo beverages next year.
Hot inflation data fuels Fed rate-hike bets, hammering chip and AI-hardware stocks while the Dow tops 52,000 and small caps hold gains; gold rebounds.
Chipotle is positioning Europe as a key growth avenue, with improving restaurant economics and strong comparable sales in Q2 2026. The company plans to expand its European development pipeline while maintaining direct ownership and operations. Chipotle's 2027 earnings are expected to grow 19.2% year-over-year, earning a Zacks Rank #2 (Buy) rating.
Krispy Kreme has been downgraded to a Zacks Rank #5 (Strong Sell) due to multiple structural challenges. The surge in GLP-1 weight-loss drug adoption is significantly reducing demand for sugary baked goods, with studies showing sweet bakery purchases plunge nearly 10% after patients start these medications. Additionally, the company faces negative revenue growth projections through 2027, chronic stock underperformance (down 78.8% over 5 years), a deteriorating balance sheet with debt-to-equity ratios nearly tripling since 2022, and a stock price below $3 that deters institutional investors.